Lv, Dongqing

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 122

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 42

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 14

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial

HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., et al. (2026) · JAMA

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 8

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced or metastatic solid tumors.

Lu, S., Zhang, Q., Meng, X., Sun, Y., Xiong, H. H., Lv, D., Wang, X., Wu, L., Dong, X., Ji, Y., et al. (2024) · Journal of Clinical Oncology

Cancer therapeutics and mechanismsMonoclonal and Polyclonal Antibodies Research

Cited by 1